

August 30, 2019

To
Department of Corporate Services
BSE Limited
P. J. Towers, Dalal Street
Fort, Mumbai - 400 001
Scrip Code: **BSE - 524500**

To
Corporate Listing Department
National Stock Exchange of India Ltd
Exchange Plaza, Plot No.C-1, G Block,
BKC, Bandra (E), Mumbai 400 051
Scrip Code: **NSE - KILITCH**

Ref: Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015

Dear Sir/Madam,

Pursuant to Regulation 30 read with Schedule III of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015 we hereby informing about the updates on Ethiopian Manufacturing Facility.

We are pleased to inform all our stakeholders that Company is nearing to complete the establishment of a world class manufacturing unit with State of the art facility at Addis Ababa, Ethiopia to cater not only to Ethiopia but all surrounding countries in an incremental way and it is expected to commence operations in the current financial year.


This expansion would ensure volume growth and better profitability in coming years ahead. We will like to update on the same as follows:

1. Construction activity has almost completed and machinery installations have started.
2. Utility Block along with QA / Admin block will be completed by September / October.
3. Validations and trial runs are planned from October onwards.
4. On successful completion of Validations and trial runs - inspection from FMHACA will be triggered.

The above is for information and dissemination to the public at large.

Thanking You,

Yours Faithfully,
For **Kilitch Drugs (India) Limited**


Mukund Mehta
Managing Director
DIN: 00147876

